LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLC
Автор: VJOncology
Загружено: 2024-09-19
Просмотров: 190
Описание:
Gerry Hanna, MBBCh, PhD, MRCP, FRCR, FRANZCR, Trinity College Dublin, Dublin, Ireland, gives an overview of safety data from the Phase III LAURA trial (NCT03521154), which evaluated osimertinib after chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC). Osimertinib significantly improved progression-free survival and the safety profile was manageable, with radiation pneumonitis (RP) and interstitial lung disease (ILD) as the most reported adverse events. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
